| TSPAN1 |
Homo sapiens |
|
TSPAN1 is differentially expressed in 98 experiments [111 up/110 dn]: 29 organism parts: kidney [3 up/0 dn], prostate [2 up/0 dn], ...; 24 disease states: normal [5 up/7 dn], breast carcinoma [2 up/0 dn], ...; 21 cell types, 29 cell lines, 20 compound treatments and 15 other conditions. |
| TSPAN1 |
|
NP_001004236.1 (Rattus norvegicus)
Tspan1 (Mus musculus)
(Compare orthologs)
|
|
|
| Tetraspanin, Tetraspanin, EC2 domain, Tetraspanin, conserved site, Tetraspanin, subgroup |
|
|
| integral to membrane, lysosome |
|
|
|
O60635
|
|
|
|
ENSG00000117472
|
|
|
| Factor Value |
Factor |
Up/Down |
Legend: - number of studies the gene is up/down in
|
|
Normal
|
Disease state |
|
|
Stromal cell
|
Cell type |
|
|
Kidney
|
Organism part |
|
|
None
|
Compound treatment |
|
|
Epithelial cell
|
Cell type |
|
|
MDA-MB-231
|
Cell line |
|
|
Prostate
|
Organism part |
|
|
Invasive ductal carcinoma
|
Histology |
|
|
BT-474
|
Cell line |
|
|
Heart
|
Organism part |
|
|
FLAP
|
Compound treatment |
|
|
0 cm away from the tumor bound...
|
Observation |
|
|
Lung
|
Organism part |
|
|
Estrogen receptor 1 positive; ...
|
Test result |
|
|
N/a
|
Test result |
|
|
Breast carcinoma
|
Disease state |
|
|
HeLa
|
Cell line |
|
|
Prostate cancer
|
Disease state |
|
|
Skeletal muscle
|
Organism part |
|
|
Peripheral blood
|
Organism part |
|
|
HNRPA2B
|
Compound treatment |
|
|
Endothelial cell
|
Cell type |
|
|
MK886
|
Compound treatment |
|
|
Primary
|
Disease staging |
|
|
Control
|
Compound treatment |
|
|
Fibroblast
|
Cell type |
|
|
PC3
|
Cell line |
|
|
HL-60
|
Cell line |
|
|
SKMEL5
|
Cell line |
|
|
BT474
|
Cell line |
|
|
White blood cells
|
Organism part |
|
|
SW480
|
Cell line |
|
|
SW620
|
Cell line |
|
|
T47D
|
Cell line |
|
|
T84
|
Cell line |
|
|
Caco-2
|
Cell line |
|
|
SsMCF7
|
Cell line |
|
|
Primary gastric tumor
|
Organism part |
|
|
MCF10A
|
Cell line |
|
|
HPL1
|
Cell line |
|
|
HaCaT
|
Cell line |
|
|
MCF7
|
Cell line |
|
|
Johnsen score count 2: Sertoli...
|
Histology |
|
|
Stage I
|
Disease staging |
|
|
Spermatid
|
Cell type |
|
|
Astrocyte
|
Cell type |
|
|
MDA468
|
Cell line |
|
|
Chondrocyte
|
Cell type |
|
|
Vascular smooth muscle cell
|
Cell type |
|
|
Trachea
|
Organism part |
|
|
Relapse 0; ER status ER+; brai...
|
Clinical info |
|
|
SkinEthic keratinocyte
|
Cell type |
|
|
Epidermal keratinocyte
|
Cell type |
|
|
Burkitt's lymphoma
|
Disease state |
|
|
Testicular seminoma
|
Disease state |
|
|
Macaca mulatta
|
Organism |
|
|
Bacterial endotoxin
|
Compound treatment |
|
|
T47-D
|
Cell line |
|
|
267B1
|
Cell line |
|
|
267B1_Ki-ras
|
Cell line |
|
|
Control
|
RNAi |
|
|
SIM2s
|
RNAi |
|
|
Bladder carcinoma
|
Disease state |
|
|
Fetal bovine serum in media
|
Growth condition |
|
|
Pretreatment primary sample
|
Clinical info |
|
|
Hypericin incubated, not irrad...
|
Growth condition |
|
|
Hypericin incubated, irradiate...
|
Growth condition |
|
|
Stage II
|
Disease staging |
|
|
Relapse 1; ER status ER+; brai...
|
Clinical info |
|
|
Tumor
|
Organism part |
|
|
U87
|
Cell line |
|
|
U373
|
Cell line |
|
|
N-nitrosodimethylamine
|
Compound treatment |
|
|
Johnsen score count 7: many ea...
|
Histology |
|
|
Smooth muscle
|
Organism part |
|
|
Vasectomized
|
Clinical history |
|
|
Johnsen score count 3.2: Serto...
|
Histology |
|
|
Keratinocyte
|
Cell type |
|
|
Met5A
|
Cell line |
|
|
Type 2B
|
Histology |
|
|
Skin
|
Organism part |
|
|
Molecular class type 1
|
Test result |
|
|
Molecular class type 2
|
Test result |
|
|
Cerebellum
|
Organism part |
|
|
Lymph node
|
Organism part |
|
|
Tonsil
|
Organism part |
|
|
Serum starvation synchronizati...
|
Growth condition |
|
|
PT1
|
Disease staging |
|
|
Methotrexate
|
Compound treatment |
|
|
Adenocarcinoma
|
Disease state |
|
|
Secretory cell
|
Cell type |
|
|
KSHV latent infection
|
Disease state |
|
|
Enzo Labeling
|
Protocol type |
|
|
Not applicable
|
Histology |
|
|
Beas2B
|
Cell line |
|
|
Synovial fluid
|
Organism part |
|
|
ERalpha transfected
|
Genotype |
|
|
ERbeta transfected
|
Genotype |
|
|
Testis
|
Organism part |
|
|
Lymphatic endothelial cell
|
Cell type |
|
|
Fetal thyroid
|
Organism part |
|
|
G3
|
Tumor grading |
|
|
Homo sapiens
|
Organism |
|
|
Bone marrow
|
Organism part |
|
|
Glucocorticoid resistant
|
Phenotype |
|
|
Epilepsy
|
Disease state |
|
|
Glucocorticoid sensitive
|
Phenotype |
|
|
Tumor cell
|
Cell type |
|
|
2-(3,4,5-trimethoxy-phenylamin...
|
Compound treatment |
|
|
Dimethyl sulfoxide
|
Compound treatment |
|
|
5-aza-2'-deoxycytidine + trich...
|
Compound treatment |
|
|
Gastric cancer
|
Disease state |
|
|
Bronchial epithelial cell
|
Cell type |
|
|
Clear cell sarcoma of the kidn...
|
Disease state |
|
|
Uterus
|
Organism part |
|
|
Crohn's disease
|
Disease state |
|
|
Pan troglodytes
|
Organism |
|
|
Adult
|
Developmental stage |
|
|
Infant
|
Developmental stage |
|
|
TIVE
|
Cell line |
|
|
AsPC-1
|
Cell line |
|
|
Epidermal growth factor
|
Compound treatment |
|
|
T3aNxM1
|
Disease staging |
|
|
Whole blood
|
Organism part |
|
|
Acute promyelocytic leukemia
|
Disease state |
|
|
U937
|
Cell line |
|
|
White blood cell
|
Cell type |
|
|
Platelet
|
Cell type |
|
|
Thyroid
|
Organism part |
|
|
PEL-5
|
Cell line |
|
|
Metastatic
|
Disease staging |
|
|
Sporadic basal-like breast can...
|
Disease state |
|
|
Chronic lymphocytic leukemia
|
Disease state |
|
|
ITS medium
|
Growth condition |
|
|
ITS medium with albumin-bound ...
|
Growth condition |
|
|
Inter-prandial lipid micelles ...
|
Growth condition |
|
|
Postprandial lipid micelles in...
|
Growth condition |
|
|
Idiopathic infertility
|
Clinical history |
|
|
Spermatocyte
|
Cell type |
|
|
Non-basal-like breast cancer
|
Disease state |
|
|
R-(-)-apomorphine HCl
|
Compound treatment |
|
|
Affymetrix Labeling
|
Protocol type |
|
|
X-linked chronic granulomatous
|
Disease state |
|
|
Atrioventricular node
|
Organism part |
|
|
Cartilage
|
Organism part |
|
|
17beta-estradiol
|
Compound treatment |
|
|
Psoriatic lesional biopsy
|
Clinical info |
|
|
Uninvolved biopsy
|
Clinical info |
|
|
Rapamycin
|
Compound treatment |
|
|
Macrophage
|
Cell type |
|
|
Monocyte
|
Cell type |
|
|
PT2
|
Disease staging |
|
|
Phenol
|
Compound treatment |
|
|
Endometrioid carcinoma
|
Disease state |
|
|
Hydroxyurea
|
Compound treatment |
|
|
Filtered air
|
Compound treatment |
|
|
Placebo
|
Compound treatment |
|
|
Glutamine
|
Compound treatment |
|
|
Estrogen receptor 1 negative; ...
|
Test result |
|
|
Glioblastoma
|
Disease state |
|
|
Acute lymphocytic leukemia
|
Disease state |
|
|
Ciliary ganglion
|
Organism part |
|
|
Normal
|
Disease staging |
|
|
Grade IV
|
Tumor grading |
|
|
PCep4 control vector transfect...
|
Gene modification |
|
|
ETat plasmid transfection
|
Gene modification |
|
|
No induction
|
Protocol type |
|
|
Native skin
|
Cell type |
|
|
Spleen
|
Organism part |
|
|
Never smoked
|
Clinical info |
|
|
Seminiferous tubule
|
Organism part |
|
|
Presymptomatic
|
Disease staging |
|
|
Current smoker
|
Clinical info |
|
|
Dorsal root ganglion
|
Organism part |
|
|
Barrett's esophagus
|
Disease state |
|
|
Moderately differentiated
|
Histology |
|
|
Unsynchronized
|
Growth condition |
|
|
Pancreas
|
Organism part |
|
|
Teratozoospermia
|
Disease state |
|
|
Normospermic
|
Disease state |
|
|
Dermatomyositis
|
Disease state |
|
|
|
|
|
Processing time: 0.433 secs.